TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as
compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT)
populations.